BioCentury
ARTICLE | Clinical News

AR-12: Phase I started

September 7, 2009 7:00 AM UTC

Arno began an open-label, dose-escalation, U.S. and European Phase I trial to evaluate oral AR-12 given for 28 consecutive days in up to 50 patients. ...